Compositions and methods for treating conditions related to increased eosinophils
Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.
1. A method of treating a condition characterized by increased numbers of eosinophils in a subject comprising:
administering to a subject in need thereof a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof, wherein the condition is selected from nasal polyposis, atopic dermatitis, eosinophilic esophagitis, hypereosinophilic syndrome, asthma, and eosinophilic gastroenteritis.
2. The method according to claim 1 , wherein the condition is hypereosinophilic syndrome.
3. The method of claim 1 , wherein the condition characterized by increased numbers of eosinophils is characterized by eosinophil numbers above about 450 cells per microliter in the peripheral blood.
4. The method of claim 1 , wherein the therapeutically effective amount is from about 50 mg to about 1,500 mg per day.
5. The method of claim 1 , wherein the therapeutically effective amount is from about 150 mg to about 1,500 mg per day.
6. The method of claim 1 , wherein the therapeutically effective amount is from about 150 mg to about 300 mg per day.
7. The method of claim 1 , wherein administering comprises administering said R(+) pramipexole or a pharmaceutically acceptable salt thereof two or more times daily.
8. The method of claim 1 , wherein administering comprises administering said R(+) pramipexole or a pharmaceutically acceptable salt thereof at a dose equal to about half of a daily dose twice per day.
9. The method of claim 8 , wherein the dose is administered every 12 hours.
10. The method of claim 1 , wherein administering comprises administering R(+) pramipexole or a pharmaceutically acceptable salt thereof at about 150 mg two times per day.
11. The method of claim 1 further comprising monitoring the patient.
12. The method of claim 1 further comprising monitoring the patient for neutropenia.
13. The method of claim 1 , further comprising an induction step.
14. The method of claim 13 , wherein said induction step comprises administering a second therapeutic agent that is capable of decreasing eosinophil levels.
15. The method of claim 13 , wherein said induction step is from about 1 week to about 6 months.
16. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 1,200 mg.
17. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 1,500 mg.
18. The method of claim 1 , wherein the condition characterized by increased numbers of eosinophils is characterized by eosinophil numbers above about 250 cells per microliter in the peripheral blood.
19. The method according to claim 1 , wherein the condition is nasal polyposis.
20. The method according to claim 1 , wherein the condition is atopic dermatitis.
21. The method according to claim 1 , wherein the condition is eosinophilic esophagitis.
22. The method according to claim 1 , wherein the condition is asthma.
23. The method according to claim 1 , wherein the condition is eosinophilic gastroenteritis.
24. The method of claim 1 , wherein therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof is administered via a route of administration selected from the group consisting of orally, ophthalmically, intravenously, intramuscularly, intraarterially, intramedullary, intrathecally, intraventricularly, transdermally, subcutaneously, intraperitoneally, intravesicularly, intranasally, enterally, topically, sublingually, rectally, by inhalation, by depot injections, by implants, by use of vaginal creams, suppositories, pessaries, vaginal rings, rectal suppositories, intrauterine devices, and transdermal forms such as patches and creams, and any combination thereof.
25. The method of claim 1 , wherein therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof is administered via a route of administration selected from the group consisting of orally, by inhalation, intranasally, via intravenous administration, topically, and any combination thereof.